Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person12
Co-Diagnostics, Inc.
Company
QUEST DIAGNOSTICS INC
Company
Lucid Diagnostics Inc.
Company
Bluejay Diagnostics, Inc.
Company
Cardio Diagnostics Holdings, Inc.
Company
Insight Molecular Diagnostics Inc.
Company
CS Disco, Inc.
Company
SERA PROGNOSTICS, INC.
Company
Cardlytics, Inc.
Company
KKR & Co. Inc.
Company
Cohen & Co Inc.
Company
Inter & Co, Inc.
Company
Primary record13
Co-Diagnostics, Inc. filed DEF 14A
SEC form DEF 14A filed by Co-Diagnostics, Inc. (CIK 1692415) on 2026-10-26.
Co-Diagnostics, Inc. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the Company ) held its previously announced Annual Meeting of Stockholders (the Annual
Co-Diagnostics, Inc. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Senior Secured Convertible Loan Transaction with J.J. Astor & Co. On October 9, 2026, Co-Diagnostics, Inc. (the Company ) entered into a Loan Agreement (the Loan Agre
Co-Diagnostics, Inc. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. As previously disclosed, on September 3, 2026, Co-Diagnostics, Inc. (the Company ) held its previously announced Annual Meeting of Stockholders (the Annual
Co-Diagnostics, Inc. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. As previously announced on September 4, 2026, on September 3, 2026, Co-Diagnostics, Inc. (the Company ) held its previously announced Annual Meeting of Stoc
Co-Diagnostics, Inc. filed 8-K
Item 7.01 Regulation FD Disclosure. On September 16, 2026, Co-Diagnostics, Inc. (the Company ) will host an investor and analyst presentation regarding, among other matters, the Company s collaboration with ReadyGo Diagn
Co-Diagnostics, Inc. filed 8-K
Item 8.01. Other Events. Press Release On September 16, 2026, Co-Diagnostics, Inc. (the Company ), issued a press release with respect to its collaboration with ReadyGo Diagnostics Ltd. A copy of the press release is att
Co-Diagnostics, Inc. filed 8-K
Item 8.01. Other Events. In August 2026, Co-Diagnostics, Inc. (the Company ) entered into a material transfer agreement with ReadyGo Diagnostics Ltd ( ReadyGo ) to evaluate the potential compatibility of certain ReadyGo
Co-Diagnostics, Inc. filed 8-K
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 3, 2026, Co-Diagnostics, Inc. (the Company ) held its previously announced Annual Meeting of Stockholders (the Annual Meeting ). However, the C
Co-Diagnostics, Inc. filed 8-K
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2026, Co-Diagnostics, Inc. (the Company ) and
ARMISTICE CAPITAL, LLC filed SCHEDULE 13G
0001172661-26-003565.txt : 20260814 SCHEDULE 13G 1 primary_doc.xml X0202 SCHEDULE 13G 0001601086 XXXXXXXX LIVE Common Stock, par value $0.001 per share 06/30/2026 0001692415 CO-DIAGNOSTICS, INC. 189763204 2401 S. Foothil
Co-Diagnostics, Inc. filed 8-K
Item 2.02. Results of Operations and Financial Condition. On August 13, 2026, Co-Diagnostics, Inc. (the Company ) issued a press release announcing financial results for its quarter ended June 30, 2026. The full text of
Co-Diagnostics, Inc. filed SCHEDULE 13G/A
0001595888-26-000088.txt : 20260810 SCHEDULE 13G/A 1 primary_doc.xml X0202 SCHEDULE 13G/A 0001595888-26-000053 0001595888 XXXXXXXX LIVE 1 Common Stock 06/30/2026 0001692415 Co-Diagnostics, Inc. 189763204 2401 S FOOTHILL